Sichuan Biokin Pharmaceutical Co. Ltd. A

Baili Tianheng announced that the company recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial of its self-developed, world-first bispecific antibody drug conjugate Yizekang, also known as luncoitab, in combination with radiotherapy for locally advanced unresectable head and neck squamous cell carcinoma and other solid tumors has been approved. To date, the drug has initiated more than 45 clinical trials in China and the United States, including 20 Phase III clinical studies, and 9 indications have been included in the breakthrough therapy designation list by the Center for Drug Evaluation.

This evening, more than 20 companies listed on the Shanghai Stock Exchange released a wave of positive signals, covering share buybacks and stake increases, strong operating results, and interim dividend returns. Four companies announced new buyback plans, with a combined proposed buyback cap of 320 million yuan. Three companies announced new stake increase plans, with a combined proposed increase cap of 166 million yuan. Another six companies disclosed progress updates on buybacks. On the operational front, Pingdingshan Tianan Coal Mining reported a 25.58 percent year-on-year rise in commercial coal sales revenue in the first half. Sichuan Biokin Pharmaceutical received clinical trial approval for its injectable drug BL-B01D1 for subcutaneous administration. Farsoon Technologies posted an 87 percent year-on-year increase in net profit attributable to the parent company in the first half. Jiangsu Beiren Robot System projected a net profit attributable to the parent company of 15.8213 million yuan for the first half of 2026, swinging to a profit. Acter Group reported a 205 percent year-on-year jump in net profit for the first half. In terms of shareholder returns, Eastroc Beverage plans to distribute approximately 2.2 billion yuan in cash dividends for the half year. OPT Machine Vision Tech disclosed that its actual controller has proposed an interim dividend arrangement. And the controlling shareholder of Lead Intelligent Equipment voluntarily committed not to reduce its stake in the company within the next 12 months.